PM EST LA JOLLA, CA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a ...
1d
An off-the-shelf immunotherapy for targeting solid tumors: Ready-to-use CAR-NKT cells show promise
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into ...
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross ...
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...
Leading GMP cell therapy CDMO I Peace, Inc. ( specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it has successfully generated human induced ...
CytoMed Therapeutics (GDTC) issued a statement to address recent statements containing “inaccurate and misleading” claims ...
On January 28, 2026, GRI Bio reported additional positive data from its recently completed Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing that RNA-sequencing gene ...
CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company"), a Singapore-based clinical stage biopharmaceutical company focused on harnessing ...
CytoMed remains committed to advancing its pipeline responsibly and to communicating accurate, timely information through official Company disclosures. The Company reserves the right to take ...
Gene Expression Data Show Direct Impact on the Core Biology of IPF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results